• Thu, March 7, 2024
Peter Lawson Maintained (TCRX) at Buy with Increased Target to $9 on, Mar 7th, 2024
Peter Lawson of Barclays, Maintained "TScan Therapeutics, Inc." (TCRX) at Buy with Increased Target from $7 to $9 on, Mar 7th, 2024.
Peter has made no other calls on TCRX in the last 4 months.
There is 1 other peer that has a rating on TCRX. Out of the 1 peers that are also analyzing TCRX, 0 agree with Peter's Rating of Hold.
This is the rating of the analyst that currently disagrees with Peter
- David Nierengarten of "Wedbush" Reiterated at Buy and Held Target at $9 on, Thursday, February 1st, 2024
